Literature DB >> 24797316

In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers.

Andre C Felicio1, Katherine Dinelle, Pankaj A Agarwal, Jessamyn McKenzie, Nicole Heffernan, Jeremy D Road, Silke Appel-Cresswell, Zbigniew K Wszolek, Matthew J Farrer, Michael Schulzer, Vesna Sossi, A Jon Stoessl.   

Abstract

INTRODUCTION: We used positron emission tomography (PET) to assess dopaminergic and serotonergic terminal density in three subjects carrying a mutation in the DCT1 gene, two clinically affected with Perry syndrome.
METHODS: All subjects had brain imaging using 18F-6-fluoro-l-dopa (FDOPA, dopamine synthesis and storage), (+)-11C-dihydrotetrabenazine (DTBZ, vesicular monoamine transporter type 2), and 11C-raclopride (RAC, dopamine D2/D3 receptors). One subject also underwent PET with 11C-3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB, serotonin transporter).
RESULTS: FDOPA-PET and DTBZ-PET in the affected individuals showed a reduction of striatal tracer uptake. Also, RAC-PET showed higher uptake in these area. DASB-PET showed significant uptake changes in left orbitofrontal cortex, bilateral anterior insula, left dorsolateral prefrontal cortex, left orbitofrontal cortex, left posterior cingulate cortex, left caudate, and left ventral striatum.
CONCLUSIONS: Our data showed evidence of both striatal dopaminergic and widespread cortical/subcortical serotonergic dysfunctions in individuals carrying a mutation in the DCTN1 gene.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Perry syndrome; dopaminergic dysfunction; dynactin gene; positron emission tomography; serotonergic dysfunction

Mesh:

Substances:

Year:  2014        PMID: 24797316      PMCID: PMC4139463          DOI: 10.1002/mds.25893

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  10 in total

1.  Density and affinity of the dopamine D2 receptors in aged symptomatic and asymptomatic MPTP-treated monkeys: PET studies with [11C]raclopride.

Authors:  Doris J Doudet; Salma Jivan; Thomas J Ruth; James E Holden
Journal:  Synapse       Date:  2002-06-01       Impact factor: 2.562

2.  Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.

Authors:  Ramachandiran Nandhagopal; Lisa Kuramoto; Michael Schulzer; Edwin Mak; Jacqueline Cragg; Jess McKenzie; Siobhan McCormick; Thomas J Ruth; Vesna Sossi; Raul de la Fuente-Fernandez; A Jon Stoessl
Journal:  Brain       Date:  2011-11       Impact factor: 13.501

3.  Dominantly inherited apathy, central hypoventilation, and Parkinson's syndrome: clinical, biochemical, and neuropathologic studies of 2 new cases.

Authors:  T L Perry; J M Wright; K Berry; S Hansen; T L Perry
Journal:  Neurology       Date:  1990-12       Impact factor: 9.910

4.  Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.

Authors:  V Kaasinen; H M Ruottinen; K Någren; P Lehikoinen; V Oikonen; J O Rinne
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

5.  [Perry and Purdy's syndrome (familial and fatal parkinsonism with hypoventilation and athymhormia)].

Authors:  Bernard Lechevalier; Françoise Chapon; Gilles Defer; Yves Rivrain; François Le Doze; Christian Schupp; Fausto Viader
Journal:  Bull Acad Natl Med       Date:  2005-03       Impact factor: 0.144

6.  Neurodegeneration involving putative respiratory neurons in Perry syndrome.

Authors:  Yoshio Tsuboi; Dennis W Dickson; Kazuki Nabeshima; Ann M Schmeichel; Zbigniew K Wszolek; Tatsuo Yamada; Eduardo E Benarroch
Journal:  Acta Neuropathol       Date:  2007-06-19       Impact factor: 17.088

7.  Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C]DASB.

Authors:  Isabelle Boileau; Jerry J Warsh; Mark Guttman; Jean A Saint-Cyr; Tina McCluskey; Pablo Rusjan; Sylvain Houle; Alan A Wilson; Jeffrey H Meyer; Stephen J Kish
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

8.  Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism.

Authors:  F J Vingerhoets; B J Snow; C S Lee; M Schulzer; E Mak; D B Calne
Journal:  Ann Neurol       Date:  1994-11       Impact factor: 10.422

9.  Pallidonigral TDP-43 pathology in Perry syndrome.

Authors:  Christian Wider; Dennis W Dickson; A Jon Stoessl; Yoshio Tsuboi; Françoise Chapon; Ludwig Gutmann; Bernard Lechevalier; Donald B Calne; David A Personett; Mary Hulihan; Jennifer Kachergus; Rosa Rademakers; Matthew C Baker; Linda L Grantier; O K Sujith; Laura Brown; Susan Calne; Matthew J Farrer; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2008-08-23       Impact factor: 4.891

10.  DCTN1 mutations in Perry syndrome.

Authors:  Matthew J Farrer; Mary M Hulihan; Jennifer M Kachergus; Justus C Dächsel; A Jon Stoessl; Linda L Grantier; Susan Calne; Donald B Calne; Bernard Lechevalier; Francoise Chapon; Yoshio Tsuboi; Tatsuo Yamada; Ludwig Gutmann; Bülent Elibol; Kailash P Bhatia; Christian Wider; Carles Vilariño-Güell; Owen A Ross; Laura A Brown; Monica Castanedes-Casey; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Nat Genet       Date:  2009-01-11       Impact factor: 38.330

  10 in total
  4 in total

Review 1.  DCTN1-related neurodegeneration: Perry syndrome and beyond.

Authors:  Takuya Konno; Owen A Ross; Hélio A G Teive; Jarosław Sławek; Dennis W Dickson; Zbigniew K Wszolek
Journal:  Parkinsonism Relat Disord       Date:  2017-06-12       Impact factor: 4.891

2.  Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering.

Authors:  Daniyal Daud; Helen Griffin; Konstantinos Douroudis; Stephanie Kleinle; Gail Eglon; Angela Pyle; Patrick F Chinnery; Rita Horvath
Journal:  J Neurol       Date:  2015-05-10       Impact factor: 4.849

3.  Establishing diagnostic criteria for Perry syndrome.

Authors:  Takayasu Mishima; Shinsuke Fujioka; Hiroyuki Tomiyama; Ichiro Yabe; Ryoichi Kurisaki; Naoki Fujii; Ryuji Neshige; Owen A Ross; Matthew J Farrer; Dennis W Dickson; Zbigniew K Wszolek; Nobutaka Hattori; Yoshio Tsuboi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-31       Impact factor: 10.154

Review 4.  Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review.

Authors:  Jarosław Dulski; Catalina Cerquera-Cleves; Lukasz Milanowski; Alexa Kidd; Emilia J Sitek; Audrey Strongosky; Ana María Vanegas Monroy; Dennis W Dickson; Owen A Ross; Jolanta Pentela-Nowicka; Jarosław Sławek; Zbigniew K Wszolek
Journal:  Eur J Neurol       Date:  2021-08-26       Impact factor: 6.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.